Riskpilot← Back to searchSign inGet full accessDisruptive Pharma AB
ABActiveOrg 5591746085UppsalaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20185-9 employees
Revenue 2024
SEK 1,2M
+27% vs 2023
EBITDA margin
-2513.6%
-17% vs 2023
Equity ratio
2.3%
Financial strength
Net profit 2024
SEK -29M
-19% vs 2023
| Revenue | SEK 1,2M | +27% |
| EBITDA | SEK -29,2M | -17% |
| Net profit | SEK -29M | -19% |
| Total assets | SEK 14,2M | -46% |
| Equity | SEK 325K | +0% |
| Employees | — | — |
Legal name
Disruptive Pharma AB
Org number
5591746085
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 oktober 2018
Share capital
SEK 50 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva utveckling, tillverkning, licensering och försäljning av läkemedel, läkemedelsprodukter, beståndsdelar till läkemedel, excipienter och hjälpämnen, tillhandahålla relaterade konsulttjänster, rådgivning, forskning och utvecklingstjänster samt driva därmed förenlig verksamhet.
Address
Uppsala
Email
stefan.strom@disruptivepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 138 | 459 | 910 | 1 160 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | — | — | −10 220 | −19 732 | −24 865 | −29 158 |
| Depreciation & amort. | −0 | −0 | −0 | −92 | −289 | −292 |
| EBIT | 0 | 0 | −10 220 | −19 824 | −25 154 | −29 450 |
| Net financials | — | — | 3 | 207 | 763 | 450 |
| Profit before tax | 0 | 0 | −10 217 | −19 617 | −24 391 | −29 000 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 0 | −10 217 | −19 617 | −24 391 | −29 000 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 50 | 50 | 17 150 | 46 260 | 26 186 | 14 203 |
| Equity | 50 | 50 | 333 | 1 716 | 325 | 325 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 16 817 | 44 544 | 25 861 | 13 878 |
| Total debt | — | — | 16 817 | 44 544 | 25 861 | 13 878 |
EBITDA margin
-2513.6%
This company
15.8%
Market median
-16009% vs market
20192024
Equity ratio
2.3%
This company
38.2%
Market median
-94% vs market
20192024
Return on equity
-8923.1%
This company
18.4%
Market median
-48595% vs market
20192024
Net profit margin
-2500.0%
This company
8.1%
Market median
-30964% vs market
20192024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20192024
Debt / equity
42.70×
This company
0.62×
Market median
-6787% vs market
20192024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-10-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DP Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
EM Chief Auditor | Chief Auditor | 2021 | — | — |
JE Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Disruptive Pharma Holding AB (publ) | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Disruptive Pharma Holding AB (publ)
Disruptive Pharma AB Board members of Disruptive Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dan Peter Åsberg | Chief Executive Officer | 0 companies |
| Eva Maria Andersson Dverstorp | Chief Auditor | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Per Stefan Ström | Deputy Board Member | 0 companies |
| Oskar Henrik Gauther Lund | Deputy Board Member | 0 companies |
| Lars-Erik Mattias Karls | Board of Directors | 0 companies |